Search

Displaying results 3051 - 3060 of 9670 in total
  1. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    The contrast agent is present as mangafodipir trisodium marketed under the name Teslascan. … Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.

  2. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722] … susceptible to rapid biotransformation and elimination as inactive metabolites.

  3. Drug

    Framycetin

    go.drugbank.com/drugs/DB00452
    ApprovedInvestigational

    On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)

    Products: Soframycin Eye Drops 5mg/ml
  4. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD. … Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.

  5. Drug

    Aluminum oxide

    go.drugbank.com/drugs/DB11342
    ApprovedWithdrawn

    Aluminum oxide has a chemical formula Al2O3. It is amphoteric in nature, and is used in various chemical, industrial and commercial applications. … It is considered an indirect additive used in food contact substances by the FDA.

  6. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

  7. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    [A275238, L54728] It is a fast-acting drug with a short duration of action. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  8. Drug

    N4-Hydroxycytidine

    go.drugbank.com/drugs/DB15660
    Experimental

    [A193023] It has shown antiviral activity against Venezuelan equine encephalitis virus,[A193008] and the human coronavirus HCoV-NL63 _in vitro_. … [A193017] N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.

  9. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. … [L54903] Tradipitant has also been investigated in gastroparesis,COVID-19-induced pneumonia, and atopic dermatitis.[A275348, A275358, A275363]

  10. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … such as [methylphenidate] and [amphetamine] that increase extracellular dopamine and norepinephrine levels.